STI-6129 CD38 ADC for the Treatment of Patients With Relapsed or Refractory Systemic ALL Amyloidosis

NCT05519527 | Withdrawn Phase 1 DMC FDA Drug

• 2 other identifiers: 2022-0113NCI-2022-07295
• Study Type: interventional
• Target: N/A
• Locations: 0 countries
• Sites: N/A

Brief Summary

This is an open-label, phase 1b/2 trial. It is designed to identify the recommended phase 2 dose (RP2D) of STI-6129, and the safety and efficacy of this anti-CD38-Duostatin 5.2 antibody-drug conjugate (ADC) for the treatment of R/R T-ALL and AML who have exhausted standard of care treatment.

Conditions

Refractory T Acute Lymphoblastic Leukemia; Acute Myeloid Leukemia (AML)

Outcome Measures

Primary Outcomes (1)

• Severity of the adverse events (Aes) -The severity of the adverse events (Aes) will be graded according to the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) V.5

  through completion of study or an average of 1 year.

Study Arms (2)

Part 1 (dose escalation)

EXPERIMENTAL

Participants of the first group will receive the lowest dose level. Participants of each new group will receive a higher dose than the group before it, if no intolerable side effects were seen. This will continue until the highest tolerable dose of STI-6129 is found.

Drug: Part 1 (STI-6129); Drug: Part 2 (STI-6129)

Part 2 (dose expansion)

EXPERIMENTAL

Participants will receive the dose of STI-6129 found in Part 1 of the study.

Drug: Part 1 (STI-6129); Drug: Part 2 (STI-6129)

Interventions

Part 1 (STI-6129) DRUG

Given by vein (IV)

Part 1 (dose escalation); Part 2 (dose expansion)

Part 2 (STI-6129) DRUG

Given by vein (IV)

Part 1 (dose escalation); Part 2 (dose expansion)

Eligibility Criteria

• Age: 18 Years+
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Age greater than or equal to 18 years.
• Confirmed diagnosis of R/R T-ALL or R/R AML by bone marrow evaluation. Note that patients must have failed treatment with available therapies known to be active for treatment of their T-ALL/AML
• ECOG performance status of 0, 1, or 2
• Pulse oximetry greater than or equal to 92% on room air
• Be willing and able to comply with the study schedule and all other protocol requirements
• Females of childbearing potential (FCBP), defined as a sexually mature woman who has not undergone a hysterectomy or tubal ligation or who has not been naturally postmenopausal for at least 24 consecutive months, must have a negative pregnancy test during the Screening Period prior to treatment. All heterosexually active FCBP and all heterosexually active male patients must agree to use effective methods of birth control throughout the study

You may not qualify if:

• A diagnosis of other malignancies if the malignancy has required therapy within the last 3 months or is not in complete remission. Exceptions are non-metastatic basal cell or squamous cell carcinomas of the skin or prostate cancer or in situ cancer that does not require further active treatment or is well under control
• Treatment with an allogeneic hematopoietic stem cell transplantation (HSCT) within 3 months prior to the planned infusion of STI-6129, or active graft-versus-host disease (GVHD) following the allogeneic transplant, or a requirement for currently receiving immunosuppressive therapy following the allogeneic transplant.
• Must be off calcineurin inhibitors for at least 4 weeks prior to study treatment.
• New York Heart Association (NYHA) class greater than or equal to 3
• Left ventricular ejection fraction (LVEF) \< 40%.
• The following baseline chemistry laboratory results at Screening:
• Serum creatinine \> 2.0 x the upper limit of normal (ULN), or estimated creatinine clearance \< 60 mL/min (using the Cockcroft-Gault equation).
• Serum aspartate aminotransferase (AST) or alanine aminotransferase (ALT) \> 3x the upper limit of normal (ULN) or serum total bilirubin \> 1.5x ULN (except for patients in or leukemia involvement)
• Pregnancy or currently breastfeeding
• Patients with greater than Grade 3 neuropathy or Grade 2 neuropathy with associated pain
• Active bacterial, viral, or fungal infection at the time of the infusion of STI-6129; patients with ongoing use of prophylactic antibiotics, antifungal agents, or antiviral agents, or infection controlled on antimicrobial agents remain eligible as long as there is no evidence of active infection
• Uncontrolled human immunodeficiency virus (HIV) infection, human T-cell leukemia virus type 1 (HTLV1) infection, or active hepatitis B virus (HBV) or hepatitis C virus (HCV) viremia or are at risk for HBV reactivation (at risk for HBV reactivation is defined as being HBs antigen positive, or anti-HBc-antibody positive), or are positive for HBV deoxyribonucleic acid (DNA). HCV ribonucleic acid (RNA) must be undetectable by laboratory test.
• Have a prolongation in QTcF (Fridericia correction formula) \> 480 msec on a baseline ECG
• Any condition including the presence of laboratory abnormalities that places the patient at an unacceptable risk if the patient was to participate in the study

Sponsors & Collaborators

• M.D. Anderson Cancer Center: lead

Related Links

• M D Anderson Cancer Center

MeSH Terms

Conditions

Precursor T-Cell Lymphoblastic Leukemia-Lymphoma; Leukemia, Myeloid, Acute

Condition Hierarchy (Ancestors)

Precursor Cell Lymphoblastic Leukemia-Lymphoma; Leukemia, Lymphoid; Leukemia; Neoplasms by Histologic Type; Neoplasms; Hematologic Diseases; Hemic and Lymphatic Diseases; Lymphoproliferative Disorders; Lymphatic Diseases; Immunoproliferative Disorders; Immune System Diseases; Leukemia, Myeloid

Study Officials

• Abhishek Maiti, MBBS

  amaiti@mdanderson.org

  PRINCIPAL INVESTIGATOR

Study Design

• Study Type: interventional
• Phase: phase 1
• Allocation: RANDOMIZED
• Masking: NONE
• Purpose: TREATMENT
• Intervention Model: CROSSOVER
• Sponsor Type: OTHER
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: August 25, 2022
• First Posted: August 29, 2022
• Study Start: August 16, 2022
• Primary Completion: February 15, 2023
• Study Completion: February 15, 2023
• Last Updated: August 31, 2023

Record last verified: 2023-08